- Stocks
- Pharma & Healthcare
- Raaj Medisafe
Raaj Medisafe share price
NSE: RAAJMEDIPharma & HealthcarePackaging & Containers
Raaj Medisafe at a glance
With a market capitalisation of ₹97 Cr, it ranks 2697th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Packaging & Containers.
Its return on equity was 24.9% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹25 Cr (+2.8% year on year) and net profit −₹3 Cr (−192.8%), on a standalone basis. Promoters held 59.08% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹97 CrRank 2697 on NSE
- Price to book
- 3.25×FY25
- EPS (TTM)
- ₹1.90to Q4 FY26
- ROE
- 24.9%FY25
- ROCE
- 18.9%FY25
- Debt to equity
- 1.49FY25
- Net profit margin
- 9.8%FY25
- Book value / share
- ₹22.60FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Raaj Medisafe quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹11 Cr | ₹13 Cr | ₹15 Cr | ₹24 Cr | ₹16 Cr | ₹18 Cr | ₹21 Cr | ₹25 Cr |
| Revenue YoY | +3.7% | +11.8% | +43.5% | +114.8% | +45.1% | +47.0% | +41.9% | +2.8% |
| Net profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | −₹3 Cr |
| Net profit YoY | +54.0% | −38.7% | +9.6% | +397.1% | +50.5% | +166.2% | +83.5% | −192.8% |
| Net margin | 8.9% | 5.2% | 7.1% | 14.3% | 9.2% | 9.4% | 9.1% | −12.9% |
| EPS | ₹0.74 | ₹0.49 | ₹0.76 | ₹2.61 | ₹1.11 | ₹1.31 | ₹1.44 | −₹1.96 |
Raaj Medisafe financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹22 Cr | ₹32 Cr | ₹35 Cr | ₹39 Cr | ₹43 Cr | ₹62 Cr |
| Operating profit | ₹0 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr |
| Net profit | −₹0 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹6 Cr |
| EPS (₹) | −₹0.30 | ₹2.07 | ₹2.82 | ₹3.06 | ₹3.07 | ₹4.60 |
| Cash from operations | −₹1 Cr | ₹2 Cr | ₹2 Cr | ₹0 Cr | ₹4 Cr | −₹0 Cr |
| Total debt | ₹8 Cr | ₹9 Cr | ₹5 Cr | ₹7 Cr | ₹14 Cr | ₹14 Cr |
| Shareholders' equity | −₹7 Cr | ₹1 Cr | ₹4 Cr | ₹7 Cr | ₹11 Cr | ₹25 Cr |
Raaj Medisafe shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 26 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 73.44% | 73.80% | 73.80% | 59.08% | 73.80% | 59.08% |
| Non-institutions | 26.56% | 26.20% | 26.20% | 40.92% | 26.20% | 40.92% |
Raaj Medisafe vs peers
The listed Pharma & Healthcare companies nearest to Raaj Medisafe by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MERCURYLABMercury Labs | — | — | — | ₹102 Cr | — | — |
| VAISHALIVaishali Pharma | ₹7.49 | +2.04% | −30.3% | ₹101 Cr | 124.8 | — |
| CONCORDConcord Drugs | — | — | — | ₹101 Cr | — | — |
| DENISCHEMDenis Chem Lab | — | — | — | ₹101 Cr | — | — |
| FORTISMLRFortis Malar | — | — | — | ₹97 Cr | — | — |
| RAAJMEDIRaaj Medisafe | — | — | — | ₹97 Cr | — | — |
| KHFMKHFM HOSPITALIT | ₹40.90 | +4.87% | −50.1% | ₹95 Cr | — | — |
Ask anything about Raaj Medisafe
Pivot answers on the live chart with evidence you can check, and tests strategies against RAAJMEDI's own history. Try: “Why has RAAJMEDI moved over the last three months?” · “Backtest a 50-day moving-average crossover on RAAJMEDI over five years” · “Compare RAAJMEDI with MERCURYLAB on margins and valuation”
Frequently asked questions about Raaj Medisafe
What is the market cap of Raaj Medisafe?
Raaj Medisafe's market capitalisation is ₹97 Cr (₹97 Cr) at the 22 Oct 2026 close, ranking 2697th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Raaj Medisafe?
Return on equity was 24.9% in FY25 and return on capital employed was 18.9% in FY25 (standalone figures).
Is Raaj Medisafe a debt-free company?
No. Raaj Medisafe's debt-to-equity ratio was 1.49 in FY25, with total debt of ₹14 Cr.
What were Raaj Medisafe's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Raaj Medisafe reported revenue of ₹25 Cr, +2.8% year on year, and net profit of −₹3 Cr, −192.8% year on year.
What is the shareholding pattern of Raaj Medisafe?
As of 30 Jun 2026: promoters 59.08%, non-institutions 40.92%.
Who are Raaj Medisafe's competitors?
The listed Pharma & Healthcare companies closest to Raaj Medisafe by market cap are Mercury Labs, Vaishali Pharma, Concord Drugs, Denis Chem Lab, Fortis Malar and KHFM HOSPITALIT.
Is Raaj Medisafe a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Raaj Medisafe's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on RAAJMEDI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text